KR20230165883A - 알츠하이머병의 치료 방법 - Google Patents

알츠하이머병의 치료 방법 Download PDF

Info

Publication number
KR20230165883A
KR20230165883A KR1020237040938A KR20237040938A KR20230165883A KR 20230165883 A KR20230165883 A KR 20230165883A KR 1020237040938 A KR1020237040938 A KR 1020237040938A KR 20237040938 A KR20237040938 A KR 20237040938A KR 20230165883 A KR20230165883 A KR 20230165883A
Authority
KR
South Korea
Prior art keywords
subject
antibody
dose
body weight
aria
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237040938A
Other languages
English (en)
Korean (ko)
Inventor
브랜든 필립 부트
제프리 조지프 세비니
레슬리 루진 윌리엄스
Original Assignee
바이오겐 인터내셔널 뉴로사이언스 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오겐 인터내셔널 뉴로사이언스 게엠베하 filed Critical 바이오겐 인터내셔널 뉴로사이언스 게엠베하
Publication of KR20230165883A publication Critical patent/KR20230165883A/ko
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51Complete heavy chain or Fd fragment, i.e. VH + CH1
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515Complete light chain, i.e. VL + CL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
KR1020237040938A 2016-06-07 2017-06-06 알츠하이머병의 치료 방법 Pending KR20230165883A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662346818P 2016-06-07 2016-06-07
US62/346,818 2016-06-07
US201662435531P 2016-12-16 2016-12-16
US62/435,531 2016-12-16
KR1020197000443A KR20190021311A (ko) 2016-06-07 2017-06-06 알츠하이머병의 치료 방법
PCT/EP2017/063711 WO2017211827A1 (en) 2016-06-07 2017-06-06 Methods for treating alzheimer's disease

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197000443A Division KR20190021311A (ko) 2016-06-07 2017-06-06 알츠하이머병의 치료 방법

Publications (1)

Publication Number Publication Date
KR20230165883A true KR20230165883A (ko) 2023-12-05

Family

ID=59067640

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020237040938A Pending KR20230165883A (ko) 2016-06-07 2017-06-06 알츠하이머병의 치료 방법
KR1020197000443A Ceased KR20190021311A (ko) 2016-06-07 2017-06-06 알츠하이머병의 치료 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020197000443A Ceased KR20190021311A (ko) 2016-06-07 2017-06-06 알츠하이머병의 치료 방법

Country Status (12)

Country Link
US (2) US20200308259A1 (enExample)
EP (1) EP3464350A1 (enExample)
JP (3) JP2019517540A (enExample)
KR (2) KR20230165883A (enExample)
CN (3) CN114796481A (enExample)
AU (2) AU2017276656A1 (enExample)
BR (1) BR112018075300A2 (enExample)
CA (1) CA3026598A1 (enExample)
IL (1) IL263433B2 (enExample)
MA (1) MA45149A (enExample)
MX (1) MX2018015022A (enExample)
WO (1) WO2017211827A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201827467A (zh) 2016-11-03 2018-08-01 比利時商健生藥品公司 焦穀胺酸類澱粉蛋白-β之抗體及其用途
EP3696192A1 (en) 2019-02-15 2020-08-19 Consejo Superior De Investigaciones Científicas Therapeutic target and monoclonal antibodies against it for the diagnosis and treatment of alzheimer´s disease
AU2020245031A1 (en) 2019-03-26 2021-10-21 Janssen Pharmaceutica Nv Antibodies to pyroglutamate amyloid-β and uses thereof
CN110511276A (zh) * 2019-08-13 2019-11-29 王跃驹 植物作为宿主在表达Aducanumab抗体中的应用
US20220372123A1 (en) * 2019-10-22 2022-11-24 Biogen Ma Inc. Anti-beta-amyloid antibody for treating alzheimer's disease
EP4185612A4 (en) 2020-07-23 2024-12-25 Othair Prothena Limited Anti-abeta antibodies
KR102321601B1 (ko) * 2020-11-19 2021-11-05 주식회사 휴런 뇌 영상을 이용한 알츠하이머병의 생물학적 분류 장치 및 방법
EP4351643A4 (en) * 2021-06-07 2025-08-06 Biogen Ma Inc METHODS OF TREATMENT OF ALZHEIMER'S DISEASE
US20250122146A1 (en) * 2021-09-30 2025-04-17 The Scripps Research Institute Compounds for reducing neuroinflammation
EP4433511A1 (en) * 2021-11-19 2024-09-25 AP Biosciences, Inc. Bispecific antibodies targeting cd137 and uses thereof for anti-cancer immunotherapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150087435A (ko) * 2006-07-14 2015-07-29 에이씨 이뮨 에스.에이. 아밀로이드 베타에 대해 인간화된 항체
ES2439490T3 (es) 2007-01-05 2014-01-23 University Of Zurich Anticuerpo anti-beta amiloide y usos del mismo
TR201812636T4 (tr) 2010-10-11 2018-09-21 Biogen Int Neuroscience Gmbh İnsan anti-tau antikorları.
WO2014060444A1 (en) * 2012-10-15 2014-04-24 Medimmune Limited Antibodies to amyloid beta
WO2014089500A1 (en) * 2012-12-07 2014-06-12 Biogen Idec International Neuroscience Gmbh A METHOD OF REDUCING BRAIN AMYLOID PLAQUES USING ANTI-Aß ANTIBODIES
CA2896066C (en) 2012-12-21 2022-07-12 Biogen Ma Inc. Human anti-tau antibodies
KR20240094017A (ko) * 2014-02-08 2024-06-24 제넨테크, 인크. 알츠하이머 질환을 치료하는 방법
MA41115A (fr) * 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer

Also Published As

Publication number Publication date
CN109476730A (zh) 2019-03-15
US20220281963A1 (en) 2022-09-08
CA3026598A1 (en) 2017-12-14
JP2025160337A (ja) 2025-10-22
WO2017211827A1 (en) 2017-12-14
MA45149A (fr) 2019-04-10
IL263433B1 (en) 2023-11-01
JP2022145965A (ja) 2022-10-04
CN114796481A (zh) 2022-07-29
IL263433A (en) 2019-01-31
CN114931635A (zh) 2022-08-23
JP2019517540A (ja) 2019-06-24
AU2024216442A1 (en) 2024-10-17
US20200308259A1 (en) 2020-10-01
IL263433B2 (en) 2024-03-01
MX2018015022A (es) 2019-08-14
EP3464350A1 (en) 2019-04-10
BR112018075300A2 (pt) 2019-04-30
AU2017276656A1 (en) 2018-12-13
KR20190021311A (ko) 2019-03-05

Similar Documents

Publication Publication Date Title
US20220281963A1 (en) Methods for treating alzheimer's disease
AU2015356773B2 (en) Method for treating Alzheimer's disease
KR20220084095A (ko) 알츠하이머병의 치료를 위한 항-베타-아밀로이드 항체
JP2024540294A (ja) アルツハイマー病を治療するための方法
CN120826223A (zh) 鲨肌醇与免疫治疗剂组合用于治疗阿尔茨海默氏病
TW202313111A (zh) 治療阿茲海默症之方法
NZ788486A (en) Methods for treating Alzheimer's disease
CN118829445A (zh) 用于治疗阿尔茨海默病的方法

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20231128

Application number text: 1020197000443

Filing date: 20190107

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20241210

Patent event code: PE09021S01D